QTTB Q32 Bio Inc.

Price (delayed)

$15.37

Market cap

$457.56M

P/E Ratio

4.91

Dividend/share

N/A

EPS

$3.13

Enterprise value

$355.2M

?
Relative Growth: Rel. Growth: 52
Relative Strength: Rel. Strength: 99
Relative Valuation: Rel. Valuation: 91
Relative Profitability: Rel. Profitability: 99

Homology Medicines, Inc. is a clinical-stage genetic medicines company historically focused on transforming the lives of patients suffering from rare diseases by addressing the underlying cause of the disease. Homology ...

Highlights
QTTB's EPS has soared by 174% YoY and by 12% from the previous quarter
QTTB's net income has surged by 165% year-on-year

Key stats

What are the main financial stats of QTTB

QTTB stock price

How has the Q32 Bio stock price performed over time
Intraday
0%
1 week
-5.12%
1 month
-28.11%
1 year
749.17%
YTD
362.95%
QTD
20.64%

Financial performance

How have Q32 Bio's revenue and profit performed over time
Revenue
$53.74M
Gross profit
$53.74M
Operating income
$21.46M
Net income
$33.79M
Gross margin
100%
Net margin
62.9%
QTTB's net income has surged by 165% year-on-year
The operating income has soared by 139% year-on-year

Price vs fundamentals

How does QTTB's price correlate with its fundamentals

Growth

What is Q32 Bio's growth rate over time

Valuation

What is Q32 Bio stock price valuation
P/E
4.91
P/B
2.46
P/S
5.82
EV/EBIT
10.51
EV/EBITDA
10.21
EV/Sales
6.61
QTTB's EPS has soared by 174% YoY and by 12% from the previous quarter
QTTB's equity has soared by 129% since the previous quarter
The P/B is 30% below the 5-year quarterly average of 3.5

Efficiency

How efficient is Q32 Bio business performance
Q32 Bio's return on invested capital has surged by 184% YoY and by 19% QoQ
The ROA has soared by 174% YoY but it has contracted by 15% from the previous quarter
The return on equity has surged by 103% year-on-year but it has dropped by 67% since the previous quarter

Dividends

What is QTTB's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for QTTB.

Financial health

How did Q32 Bio financials performed over time
The total liabilities has plunged by 87% YoY and by 43% from the previous quarter
The total assets has surged by 82% since the previous quarter and by 75% year-on-year
QTTB's debt is 96% smaller than its equity
QTTB's equity has soared by 129% since the previous quarter
Q32 Bio's debt to equity has soared by 103% YoY but it has plunged by 86% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.